Market Overview

UPDATE: Morgan Stanley Raises PT on Baxter International on Neutral Risk-Reward

Share:
Related BAX
GE And Other Companies In Transition That Insiders Are Buying
Short Interest In Abbott Labs And Baxter International Doubles
Baxter International: CEO Insider's $500,000 Share Purchase Is A Vote Of Confidence (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Baxter International (NYSE: BAX), and raised the price target from $71.00 to $84.00.

In the report, Lewis noted, “We see a neutral risk-reward into Baxter's highly-anticipated PIII Alzheimer's data. We estimate the stock price currently includes roughly $3-5 in AD optionality, placing likely downside at 3-10% for a total failure (missed primary endpoints, missed subgroup analyses). Upside in the unlikely (p=5%) case of success on both primary endpoints could be $6-11, or 8-15%. Several intermediate cases of mixed results or suggestive subgroup analyses could drive less extreme outcomes and will likely punt investment implications until the presentation of full data results.”

Baxter International closed on Friday at $70.94.

Latest Ratings for BAX

DateFirmActionFromTo
May 2016Evercore ISI GroupInitiates Coverage onBuy
Apr 2016Credit SuisseMaintainsNeutral
Apr 2016Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BAX)

View Comments and Join the Discussion!